

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:1. (Currently amended) A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen-presenting cell (APC), wherein the first agent comprises a substantially pure mutant IL-15 polypeptide comprising a mutation at position 149 or position 156 of SEQ ID NO:4, and wherein the second agent comprises a substantially pure polypeptide that binds a B7 molecule.

2.-3. (Canceled)

4. (Currently amended) The therapeutic composition of ~~claim 3~~ claim 1, wherein the mutant IL-15 polypeptide ~~has~~ comprises a mutation at position 149 of ~~SEQ ID NO:2~~ SEQ ID NO:4.

5. (Currently amended) The therapeutic composition of ~~claim 3~~ claim 1, wherein the mutant IL-15 polypeptide ~~has~~ comprises a mutation at position 156 of ~~SEQ ID NO:2~~ SEQ ID NO:4.

6. (Currently amended) The therapeutic composition of claim 5, wherein the mutant IL-15 polypeptide ~~also has~~ further comprises a mutation at position 149 of ~~SEQ ID NO:2~~ SEQ ID NO:4.

7. (Currently amended) The therapeutic composition of claim 5, wherein the mutation at position 156 of ~~SEQ ID NO:2~~ SEQ ID NO:4 is a substitution of aspartate for glutamine.

8. (Currently amended) The therapeutic composition of ~~claim 6~~, claim 4, wherein the mutation at position 149 of ~~SEQ ID NO:2~~ SEQ ID NO:4 is a substitution of aspartate for

glutamine.

9. (Currently amended) The therapeutic composition of ~~claim 6~~ claim 6, wherein the mutant IL-15 polypeptide has a substitution of aspartate for glutamine at positions 149 and 156 of ~~SEQ ID NO:2~~ SEQ ID NO:4.

10. (Currently amended) The therapeutic composition of ~~claim 2~~ claim 1, wherein the first agent further comprises a moiety that leads to the elimination of IL-15R-bearing cells.

11. (Currently amended) The therapeutic composition of claim 10, wherein the moiety that lyses IL-15R-bearing cells is an Fc region of an IgG or an IgM molecule.

12.-13. (Canceled).

14. (Currently amended) The therapeutic composition of ~~claim 13~~ claim 1, wherein the B7 molecule is B7-1.

15. (Currently amended) The therapeutic composition of ~~claim 13~~ claim 1, wherein the B7 molecule is B7-2.

16. (Currently amended) The therapeutic composition of ~~claim 13~~ claim 1, wherein the polypeptide that binds B7 is a polypeptide comprising CTLA4/Ig.

17. (Currently amended) The therapeutic composition of ~~claim 13~~ claim 1, wherein the polypeptide that binds B7 comprises an anti-B7 antibody.

18.-41. (Canceled)

42. (Currently amended) A method of making ~~[[a]] the therapeutic composition of claim 1, comprising a mutant IL-15 polypeptide that binds a subunit of an IL-15R and a polypeptide that binds a B7 molecule;~~ the method comprising

(a) purifying the mutant IL-15 polypeptide from ~~[[an]]~~ a first expression system, wherein

the first expression system comprises cells that comprise a nucleic acid molecule that encodes the mutant IL-15 polypeptide; and

(b) purifying the polypeptide that binds B7 from [[an]] a second expression system, wherein the second expression system comprises cells that comprise a nucleic acid molecule that encodes the polypeptide that binds B7; and

(c) combining the IL-15 polypeptide and the polypeptide that binds B7.

43. (New) The method of claim 42, wherein the mutant IL-15 polypeptide comprises a mutation at position 149 of SEQ ID NO:4.

44. (New) The method of claim 42, wherein the mutant IL-15 polypeptide comprises a mutation at position 156 of SEQ ID NO:4.

45. (New) The method of claim 44, wherein the mutant IL-15 polypeptide further comprises a mutation at position 149 of SEQ ID NO:4.

46. (New) The method of claim 44, wherein the mutation at position 156 of SEQ ID NO:4 is a substitution of aspartate for glutamine.

47. (New) The method of claim 45, wherein the mutation at position 149 of SEQ ID NO:4 is a substitution of aspartate for glutamine.

48. (New) The method of claim 45, wherein the mutant IL-15 polypeptide has a substitution of aspartate for glutamine at positions 149 and 156 of SEQ ID NO:4.